“Carglass- & Moleskine-Wette: D’Ieteren” - T-Mobile x Telekom, UnitedHealth & ADRs

The episode opens with UnitedHealth Group reporting stronger-than-expected quarterly results, with the medical loss ratio falling below 84% against analyst expectations of 86% — the lowest in two years. The stock rose 7% on the day and nearly 30% over the prior month. The host contextualizes UnitedHealth's valuation: while trading at roughly 20x forward earnings (a market cap of ~$315 billion), it trades at only 10x earnings relative to its peak years of 2023–2024, suggesting significant recovery potential. The company is noted as more than just a health insurer — it employs doctors, runs large medical clinics, and sells software to other healthcare companies. UnitedHealth is investing $1.5 billion in AI this year alone, with plans to monetize AI tools through software sales to customers within one to two years. However, the host cautions that this remains a complex turnaround story requiring strong management execution, noting that half of the top 100 managers have been replaced recently.

Briefly mentioned are Magnum Ice Cream (owned by Unilever), which faces headwinds from weather dependency, health trends, logistics/cooling costs, and rising energy prices — with about 19% of shares shorted, making it one of the most shorted stocks in the Euro 600. Royal Unibrew dropped 25% after it was revealed that its Pepsi bottling contract for Denmark, the Baltic states, and Finland (representing ~13% of sales) will transfer to Carlsberg from 2029, illustrating the risks of customer concentration. Amazon's additional $5 billion investment in Anthropic was noted as a positive catalyst, with the potential for up to $20 billion total, alongside Anthropic committing $100 billion in cloud computing spend with AWS over 10 years. Halliburton, Carex (world's largest condom manufacturer, citing price hikes and supply chain bottlenecks), VW's new budget electric SUV Jetta X at ~€10,000, and a leaked SpaceX IPO prospectus detail (Musk's $1.4 billion share buyback from employees and a massive bonus tied to a $6,600 billion valuation target) are also briefly covered. Deutsche Telekom and T-Mobile US are reportedly in early-stage merger discussions, which could create the world's most valuable telecom company, though share prices barely reacted.

The main analytical segment focuses on D'Ieteren Group as an indirect play on the anticipated Bellron (Carglass parent) IPO. Bellron is expected to go public at a valuation of at least €30 billion, which would represent over 50x earnings — steep, though Bellron has averaged 20% operating profit growth over 10 years. D'Ieteren owns 50% of Bellron, meaning its stake alone would be worth nearly €11 billion at the IPO valuation — far exceeding D'Ieteren's current total market capitalization. Even after accounting for D'Ieteren's net debt, the remaining businesses (including the VW importer for Belgium, spare parts retailer TVH, KFZ parts dealer PHE, and Moleskine notebooks) would be acquired nearly for free, despite generating €140 million in net profit. However, several risks are flagged: the IPO is not guaranteed at that valuation, private equity beautification of financials before IPOs is common, D'Ieteren's controlling family previously issued a debt-financed special dividend to buy out a large shareholder (raising governance concerns), a typical holding discount applies, and most of D'Ieteren's other businesses are currently struggling — particularly Moleskine, which reportedly cannot cover its interest payments.

The episode closes with a sponsored segment featuring Julius Weller, VP Broker at Scalable Capital, explaining why some stocks are unavailable on German broker platforms. Key requirements include a Legal Entity Identifier (LEI) for all EU-traded instruments and a settlement declaration from Clearstream AG. Companies sometimes lack these at IPO (e.g., Coinbase initially), delaying availability. Scalable actively contacts investor relations teams to resolve this. Weller also warns about ADRs (American Depositary Receipts) — US bank instruments that allow European stocks to trade in the US with a US ISIN. These are not direct share ownership, may carry fees that reduce dividend payouts, trade in dollars rather than local currency, and can be terminated by the issuing bank at any time.